Spark Therapeutics Inc.'s pleasing phase III top-line data with its compound for blindness-causing, RPE65-mediated, inherited retinal dystrophies (IRDs) whetted investor appetite for more-detailed results and sent hope surging through the sector, as SPK-RPE65 could become the first gene therapy cleared for marketing in the U.S. Read More
Playing to a mixed audience of boos and cheers, the Trans-Pacific Partnership (TPP) was finalized Monday with the U.S. agreeing to biologic exclusivity of five to eight years. Read More
Florida-based drug developers, Biscayne Pharmaceuticals Inc. and Insero Health Inc., have merged to advance a synthetic version of a traditional Chinese medicine (TCM) – into phase Ib/IIa proof of concept in epilepsy by mid- to late 2016 and a cancer compound headed for investigational new drug application-enabling studies. Read More
LONDON – Bowing to the inevitable, industry bodies in the UK have collaborated with payers and regulators in publishing a guide to biosimilars, to inform staff in the National Health Service (NHS) on their adoption. Read More
Exonate Ltd., of Cambridge, UK, said it closed a funding round, including investment from the Angel Cofund, which brings the total amount raised to almost £800,000 (US$1.2 million) to date. Read More
Contravir Pharmaceuticals Inc., of Edison, N.J., disclosed preliminary data on the properties of CMX157, the company's lipid prodrug of the antiviral drug tenofovir (Viread, Gilead Pharmaceuticals Inc.). Read More
